quidelortho - QDEL
QDEL
Close Chg Chg %
15.60 -0.87 -5.58%
Open Market
14.73
-0.87 (5.58%)
Volume: 1.03M
Last Updated:
Mar 27, 2026, 2:12 PM EDT
Company Overview: quidelortho - QDEL
QDEL Key Data
| Open $15.35 | Day Range 14.71 - 15.78 |
| 52 Week Range 15.08 - 38.99 | Market Cap $1.06B |
| Shares Outstanding 68.08M | Public Float 67.38M |
| Beta 0.75 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$16.66 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.64M |
QDEL Performance
| 1 Week | 2.36% | ||
| 1 Month | -31.40% | ||
| 3 Months | -46.76% | ||
| 1 Year | -55.29% | ||
| 5 Years | -87.65% |
QDEL Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
9
Full Ratings ➔
About quidelortho - QDEL
QuidelOrtho Corp. operates as a vitro diagnostics company. It is focused on developing and manufacturing diagnostic products. The company was founded on May 27, 2022 and is headquartered in San Diego, CA.
QDEL At a Glance
QuidelOrtho Corp.
9975 Summers Ridge Road
San Diego, California 92121
| Phone | 1-800-552-1100 | Revenue | 2.73B | |
| Industry | Medical Specialties | Net Income | -1,131,800,000.00 | |
| Sector | Health Technology | Employees | 6,500 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
QDEL Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.728 |
| Price to Book Ratio | 1.036 |
| Price to Cash Flow Ratio | 18.88 |
| Enterprise Value to EBITDA | 9.418 |
| Enterprise Value to Sales | 1.705 |
| Total Debt to Enterprise Value | 0.609 |
QDEL Efficiency
| Revenue/Employee | 419,538.462 |
| Income Per Employee | -174,123.077 |
| Receivables Turnover | 4.77 |
| Total Asset Turnover | 0.428 |
QDEL Liquidity
| Current Ratio | 1.498 |
| Quick Ratio | 0.90 |
| Cash Ratio | 0.176 |
QDEL Profitability
| Gross Margin | 39.677 |
| Operating Margin | 1.90 |
| Pretax Margin | -40.62 |
| Net Margin | -41.503 |
| Return on Assets | -17.772 |
| Return on Equity | -46.149 |
| Return on Total Capital | -23.805 |
| Return on Invested Capital | -23.005 |
QDEL Capital Structure
| Total Debt to Total Equity | 147.561 |
| Total Debt to Total Capital | 59.606 |
| Total Debt to Total Assets | 49.12 |
| Long-Term Debt to Equity | 136.751 |
| Long-Term Debt to Total Capital | 55.239 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Quidelortho - QDEL
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 3.26B | 2.99B | 2.79B | 2.73B | |
Sales Growth
| +92.11% | -8.26% | -6.95% | -2.10% | |
Cost of Goods Sold (COGS) incl D&A
| 1.46B | 1.71B | 1.70B | 1.65B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 283.60M | 457.20M | 453.40M | 442.00M | |
Depreciation
| 151.10M | 252.40M | 250.00M | 252.80M | |
Amortization of Intangibles
| 132.50M | 204.80M | 203.40M | 189.20M | |
COGS Growth
| +241.84% | +16.98% | -0.62% | -3.21% | |
Gross Income
| 1.80B | 1.28B | 1.09B | 1.08B | |
Gross Income Growth
| +41.73% | -28.75% | -15.39% | -0.36% | |
Gross Profit Margin
| +55.20% | +42.87% | +38.99% | +39.68% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 811.50M | 1.01B | 985.50M | 932.50M | |
Research & Development
| 190.50M | 246.80M | 218.70M | 186.20M | |
Other SG&A
| 621.00M | 763.20M | 766.80M | 746.30M | |
SGA Growth
| +128.56% | +24.46% | -2.43% | -5.38% | |
Other Operating Expense
| 12.30M | 27.10M | 51.80M | 97.70M | |
Unusual Expense
| 160.00M | 113.40M | 2.01B | 979.10M | |
EBIT after Unusual Expense
| 817.40M | 132.90M | (1.96B) | (927.30M) | |
Non Operating Income/Expense
| (7.50M) | (44.50M) | 43.60M | 15.50M | |
Non-Operating Interest Income
| - | - | 28.00M | 10.20M | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 74.00M | 117.50M | 217.00M | 195.90M | |
Interest Expense Growth
| +10,471.43% | +58.78% | +84.68% | -9.72% | |
Gross Interest Expense
| 74.00M | 117.50M | 217.00M | 195.90M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 735.90M | (29.10M) | (2.13B) | (1.11B) | |
Pretax Income Growth
| -18.27% | -103.95% | -7,224.74% | +48.03% | |
Pretax Margin
| +22.55% | -0.97% | -76.52% | -40.62% | |
Income Tax
| 187.20M | (19.00M) | (79.50M) | 24.10M | |
Income Tax - Current - Domestic
| 211.00M | (50.90M) | 3.80M | (900.00K) | |
Income Tax - Current - Foreign
| 17.60M | 36.40M | 22.10M | 24.90M | |
Income Tax - Deferred - Domestic
| (41.20M) | 4.90M | (129.90M) | (4.30M) | |
Income Tax - Deferred - Foreign
| (200.00K) | (9.40M) | 24.50M | 4.40M | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 548.70M | (10.10M) | (2.05B) | (1.13B) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 548.70M | (10.10M) | (2.05B) | (1.13B) | |
Net Income Growth
| -22.08% | -101.84% | -20,216.83% | +44.84% | |
Net Margin Growth
| +16.82% | -0.34% | -73.67% | -41.50% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 548.70M | (10.10M) | (2.05B) | (1.13B) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 548.70M | (10.10M) | (2.05B) | (1.13B) | |
EPS (Basic)
| 9.6602 | -0.1512 | -30.5357 | -16.6932 | |
EPS (Basic) Growth
| -42.28% | -101.57% | -20,095.57% | +45.33% | |
Basic Shares Outstanding
| 56.80M | 66.80M | 67.20M | 67.80M | |
EPS (Diluted)
| 9.5592 | -0.1512 | -30.5357 | -16.6932 | |
EPS (Diluted) Growth
| -41.80% | -101.58% | -20,095.57% | +45.33% | |
Diluted Shares Outstanding
| 57.40M | 66.80M | 67.20M | 67.80M | |
EBITDA
| 1.26B | 703.50M | 502.00M | 493.80M | |
EBITDA Growth
| +29.97% | -44.21% | -28.64% | -1.63% | |
EBITDA Margin
| +38.64% | +23.50% | +18.02% | +18.11% |
Snapshot
| Average Recommendation | HOLD | Average Target Price | 33.714 | |
| Number of Ratings | 9 | Current Quarters Estimate | 0.445 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | 2.146 | |
| Last Quarter’s Earnings | 0.46 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 2.12 | Next Fiscal Year Estimate | 2.906 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 7 | 7 | 7 | 7 |
| Mean Estimate | 0.45 | 0.10 | 2.15 | 2.91 |
| High Estimates | 0.63 | 0.16 | 2.22 | 3.43 |
| Low Estimate | 0.30 | -0.01 | 2.00 | 2.45 |
| Coefficient of Variance | 28.28 | 56.72 | 3.39 | 11.71 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 2 | 2 | 2 |
| OVERWEIGHT | 1 | 1 | 1 |
| HOLD | 5 | 5 | 5 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 1 | 1 | 1 |
| MEAN | Hold | Hold | Hold |
SEC Filings for Quidelortho - QDEL
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Quidelortho - QDEL
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Feb 20, 2026 | Joseph Michael Busky Chief Financial Officer | 10,290 | Open market or private purchase of non-derivative security Non-derivative transaction at $23.66 per share | 243,461.40 |
| Nov 26, 2025 | Kenneth J. Widder Director | 37,061 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $27.81 per share | 1,030,666.41 |
| Nov 26, 2025 | Kenneth J. Widder Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Nov 26, 2025 | Kenneth J. Widder Director | 41,087 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $15.74 per share | 646,709.38 |
| Nov 21, 2025 | Michelle A. Hodges Chief Legal Officer | 10,698 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Nov 21, 2025 | Brian J. Blaser President and CEO | 29,533 | Open market or private purchase of non-derivative security Non-derivative transaction at $21.34 per share | 630,234.22 |
| Nov 21, 2025 | Michelle A. Hodges Chief Legal Officer | 34,752 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 21, 2025 | Michelle A. Hodges Chief Legal Officer | 32,035 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $21.28 per share | 681,704.80 |
| Sep 18, 2025 | Lee Bowman Chief Human Resources Officer | 1,647 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $28.92 per share | 47,631.24 |
| Sep 18, 2025 | Lee Bowman Chief Human Resources Officer | 5,132 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Sep 18, 2025 | Lee Bowman Chief Human Resources Officer | 2,565 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 21, 2025 | Ann D. Rhoads Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 21, 2025 | Ann D. Rhoads Director | 8,687 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 21, 2025 | Mary Lake Polan Director | 6,583 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 21, 2025 | Kenneth F. Buechler Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 21, 2025 | Kenneth F. Buechler Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 21, 2025 | Kenneth F. Buechler Director | 87,777 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 21, 2025 | Kenneth F. Buechler Director | 87,541 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 21, 2025 | Ann D. Rhoads Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 21, 2025 | Edward L. Michael Director | 16,257 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |